A major new project, led by a University of Birmingham immunologist is one of three new UK-wide studies that will receive funding from UKRI and NIHR to understand immune responses to the novel coronavirus.
The UK Coronavirus Immunology Consortium (UK-CIC) will receive £6.5 million to bring together leading immunologists from 17 research institutions
A major new project, led by a University of Birmingham immunologist is one of three new UK-wide studies, bringing together scientists from 17 research institutions, that will receive a share of £8.4 million from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR) to understand immune responses to the novel coronavirus.
The scientists aim is to develop better tests to define immunity, to study the body’s immune response to SARS-CoV-2 and to understand why some people suffer from severe life-threatening COVID-19 while others have mild or asymptomatic infections but can still transmit the virus. Importantly these studies will determine when and how immunity persists or whether people can become re-infected.
Together, it is hoped these studies will improve the treatment of patients and inform the development of vaccines and therapies.
Led by Professor Paul Moss from the University of Birmingham’s Institute of Immunology and Immunotherapy, the UK Coronavirus Immunology Consortium (UK-CIC) will receive £6.5 million to bring together leading immunologists from 17 research institutions*. The consortium will investigate key questions including:
Better understanding of these immune responses, particularly the T cell response, could provide targets for new therapies to treat COVID-19 and inform the efforts to develop a vaccine.
The project will use samples and data from major UK COVID-19 projects already underway, and funded by UKRI and NIHR, including ISARIC-4C (characterizing and following more than 75,000 hospitalized patients with COVID-19) and the genomic studies COG-UK (sequencing the SARS-CoV-2 virus genomes) and GenOMICC (sequencing the genomes of people with COVID-19).
Professor Paul Moss said: “Understanding the complexities of the immune response to SARS-CoV-2 is key to successfully developing new diagnostics, treatments and vaccines against COVID-19. The UK Coronavirus Immunology Consortium will see the UK immunology community come together in an unprecedented way to answer questions that are crucial in helping us control this pandemic, such as how effective immunity is developed and why individuals respond differently to the disease.
“The UK is a world leader in immunology research and it’s an honour to lead this consortium to deliver a co-ordinated and agile national research programme to build our knowledge of this disease, which will translate into meaningful benefit for patients. There is so much that we still need to learn about how the novel coronavirus interacts with our immune systems and, with this investment, we have a unique opportunity to answer these key questions and hasten effective pandemic control.”
Medical Research Council, part of UKRI, Chief Executive Professor Fiona Watt said: “The UK is funding a collaboration of world-leading immunologists to investigate the major unanswered questions related to coronavirus immunity. Finding out more about the immune response to COVID-19 will be key to developing better treatments and vaccines and improving public health strategies.”
Chief Medical Officer for England and Head of the NIHR Professor Chris Whitty said: “Understanding how our immune systems respond to COVID-19 is key to solving some of the important questions about this new disease, including whether those who have had the disease develop immunity and how long this lasts, and why some are more severely affected.
“This investment by the NIHR and UKRI will help immunology experts to discover how our immune systems respond to SARS-CoV-2, including our T cell response. This is vital information to help prevent and treat the disease.”
Science Minister Amanda Solloway said:“Thanks to the brilliant work of our world-leading scientists and researchers, we continue to gain greater knowledge and understanding of coronavirus, enabling us to rapidly develop new treatments, as well as potential new vaccines.
“These three studies will help further improve our understanding of people’s immune responses to coronavirus, ensuring that the UK continues to play a critical role in the global effort to treat and defeat it.”
These studies build on the UK’s world-class expertise and capability in global heath and infectious disease that has already shaped our understanding of the pandemic and is informing measures to tackle it.
For more information please contact Sophie Belcher, Communications Manager, University of Birmingham, on +44 7815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.
For further information or to speak to one of the researchers involved, please contact the UKRI external communications team on 01793 298902.
*The full list of research institutions include the University of Birmingham, University of Bristol, University of Cambridge and Wellcome Sanger Institute, UCL, King’s College London, Imperial College London, University of Liverpool, University of Manchester, Newcastle University, University of Oxford, University of Sheffield, University of York, Cardiff University, University of Dundee, University of Edinburgh, University of Glasgow and the Bradford Institute for Health Research.
UK Research and Innovation works in partnership with universities, research organisations, businesses, charities, and government to create the best possible environment for research and innovation to flourish. We aim to maximise the contribution of each of our component parts, working individually and collectively. We work with our many partners to benefit everyone through knowledge, talent and ideas.
Operating across the whole of the UK with a combined budget of more than £8 billion, UK Research and Innovation brings together the seven research councils, Innovate UK and Research England.
The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
The NIHR was established in 2006 to improve the health and wealth of the nation through research and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.
Learn about other studies that have been given urgent public health status and the single, national prioritisation process that has been established to prevent duplication of effort and to ensure that the resources and capacity of the health and care system to support COVID-19 research are not exceeded.
